| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | 1.038 | dpa-AFX | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| 15:14 | Protagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology Annual Meeting | 531 | ACCESS Newswire | One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further... ► Artikel lesen | |
| 07:10 | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | 477 | GlobeNewswire (Europe) | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Halle (Saale) / Munich, Germany... ► Artikel lesen | |
| 07:07 | Megatrend Nanotechnologie rückt in den Fokus der Kapitalmärkte | Small- & Micro Cap Investment | |||
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.03.2026 | 475 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.03.2026.ISIN NameCA98420Q3061 XORTX... ► Artikel lesen | |
| 12:07 | Wunder-Mittel: Querschnittlähmung und Erblindung werden heilbar?! | bullVestor | |||
| Fr | Nymox Pharmaceutical Corporation: NYMOX Provides Recent Updates | 370 | ACCESS Newswire | IRVINE, CA / ACCESS Newswire / March 27, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) will be shortly updating the Board of Directors. Patrick Doody has retired from... ► Artikel lesen | |
| Fr | Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates | 145 | GlobeNewswire (Europe) | EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis - FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments... ► Artikel lesen | |
| Fr | Cue Biopharma, Inc.: Cue Biopharma Announces CEO Transition | 83 | GlobeNewswire (Europe) | BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and... ► Artikel lesen | |
| Fr | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 78 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| Fr | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights | 71 | GlobeNewswire (Europe) | Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its... ► Artikel lesen | |
| Fr | BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency | 69 | GlobeNewswire (Europe) | NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American... ► Artikel lesen | |
| Fr | ZIVO Bioscience Provides Special Letter to Shareholders | 62 | Business Wire | TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
Dear Fellow... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 46,050 | 2,47 | +5,36 % | 2,25 | 23.03.2026 | |
| CSL | 85,30 | 2,61 | +3,06 % | 1,84 | 10.03.2026 | |
| BML | 22,600 | 0,65 | +2,88 % | 60,00 | 30.03.2026 | |
| AMGEN | 306,75 | 8,37 | +2,73 % | 2,52 | 15.05.2026 | |
| NOVONESIS | 50,36 | 0,87 | +1,73 % | 4,25 | 20.03.2026 | |
| GENUS | 29,000 | 0,38 | +1,31 % | 0,11 | 05.03.2026 | |
| STRYKER | 290,00 | 2,98 | +1,03 % | 0,88 | 31.03.2026 | |
| BIOMERIEUX | 90,25 | 0,90 | +1,00 % | 0,98 | 09.06.2026 | |
| BIO-TECHNE | 44,000 | 0,27 | +0,61 % | 0,08 | 13.02.2026 | |
| REGENERON PHARMACEUTICALS | 656,20 | 3,02 | +0,46 % | 0,94 | 20.02.2026 |